Genmab A GMAB
NASDAQ GMAB
$53.16 -0.91 (-1.68%)
As of: Nov 11, 2026 · 11:25 AM EST

Genmab A (GMAB) Gross Margin (2023 - 2026)

Updated

Genmab A (GMAB) reported Gross Margin of 92.73% for the quarter ended Jun 30, 2026, down 0.02 percentage points from the prior quarter.

Analysis

Genmab A (GMAB) Gross Margin (2023 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Genmab A's Gross Margin came in at 93.40%; for the year ended Dec 31, 2025, it came in at 93.60%, down 1.82 percentage points from the prior year.

  • By year, Gross Margin came in at 95.42% in the year ended Dec 31, 2024 (-3.20 pp) and 98.62% in the year ended Dec 31, 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 83.88%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 68.12%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 75.38%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 72.95%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 88.03%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 73.10%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 81.07%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 75.71%
10 Genmab A 3.47 Bn -3.13 Bn 1.10 Bn 92.59%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 92.59%
Jun 30, 2026 92.73%
Mar 31, 2026 92.75%
Sep 30, 2025 94.32%
Jun 30, 2025 93.84%
Mar 31, 2025 94.13%
Sep 30, 2024 95.10%
Jun 30, 2024 96.41%
Mar 31, 2024 95.52%
Sep 30, 2023 98.32%
API Access

Genmab A Gross Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gross-margin&ticker=GMAB&period=max&api_key=YOUR_API_KEY